RM Global Partners
VC Fund
New York, United States
RM Global Partners is a VC fund in New York focused on Biotechnology and Health Care. RM Global is an investment banking and strategic advisory firm dedicated to creating unique value for its clients and investors. We specialize in Life Sciences, including pharmaceuticals, medical devices, biotechnology, healthcare IT/digital health, and diagnostics. Our broad international reach includes the Americas, Europe, Israel, and Asia.Since 1992, our diverse team of accomplished professionals has worked closely with life science companies ranging from start-ups to multinationals, providing unbiased strategic and financial advice, based upon our comprehensive industry experience. Several of our partners were senior management of Roberts Mitani, which completed over $3 billion in M&A and strategic transactions and raised over $200 million in private growth and venture capital for clients. We take pride in our long term relationships with our clients that span many years.We leverage our unique global network of leading corporations, investment funds, institutional and strategic investors, family offices, industry experts and management teams to source and execute transactions that build new opportunities for our clients worldwide.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
- Fund size:
- $64M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries RM Global Partners invests in
Stages RM Global Partners invests in
Countries RM Global Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Series A
- $18M–$20M
- Series B
- $32M–$140M
Investment Focus
Industry
- Biotechnology 3 (75%)
- Health Care 2 (50%)
- Life Science 2 (50%)
- Therapeutics 1 (25%)
Stage
- Series A 2 (50%)
- Series B 2 (50%)
Country
- Israel 2 (50%)
- United States 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bruce E. Roberts
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Lisa Wisniewski
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ImmPACT Bio
|
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues. | $139.9M / Series B / Jan 20, 2022 | |
|
ImmPACT Bio
|
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues. | $18M / Series A / Aug 18, 2020 | |
BIOMx
|
BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators:Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology. | $32M / Series B / Feb 20, 2019 | |
Mitoconix Bio
|
Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases.Mitochondria generates ATP, the energy source for all cellular activities. Mitochondria are also involved in other essential cellular functions, including calcium sequestration, amino acid and lipid metabolism,keeping balanced redox potential and orchestrating programmed cell death. In neurons in particular, mitochondria are very dynamic organelles that constantly undergo fission (division) and fusion. This process, called mitochondrial dynamics, is critical in maintaining healthy and functional mitochondria under both normal conditions and in response to stress and in ensuring having viable mitochondria along the axons and in the synaptic boutons. A defect in either fusion or fission limits mitochondrial motility, decreases energy production, increases oxidative stress and activates pro-apoptotic signaling thereby promoting cell dysfunction and death.Mitoconix’ lead drug is a first-in-class inhibitor of pathological mitochondrial fragmentation and dysfunction with demonstrated in vivo efficacy in animal models of Huntington’s (HD) and Parkinson’s diseases (PD) and beneficial activity in patient-derived cells of HD, sporadic and genetic PD, and sporadic and genetic Alzheimer’s disease (AD). | $20M / Series A / Jun 27, 2017 |
Co-Investors
OrbiMed
4 deals together
Bukwang Pharmaceutical Co
2 deals together
Foresite Capital
2 deals together
Novartis Venture Fund
2 deals together
Takeda Ventures
2 deals together
venBio Partners
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does RM Global Partners invest in?
RM Global Partners invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is RM Global Partners's check size?
RM Global Partners typically joins rounds of $18M–$20M at Series A and $32M–$140M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds RM Global Partners participates in.
How do I contact RM Global Partners?
Public channels for RM Global Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at RM Global Partners?
The team at RM Global Partners includes Bruce E. Roberts (Managing Director) and Lisa Wisniewski (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
